<DOC>
	<DOCNO>NCT00989807</DOCNO>
	<brief_summary>This program provide expand access aztreonam lysine inhalation ( AZLI ) prior commercial availability patient cystic fibrosis ( CF ) chronic P. aeruginosa airway infection limit treatment option risk disease progression .</brief_summary>
	<brief_title>Expanded Access Program Aztreonam Lysine Inhalation Canadian Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>≥ 6 year age Patient CF diagnose one following : Documented sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test , Two well characterize genetic mutation CFTR gene , Abnormal nasal potential difference accompany symptom characteristic CF PA present expectorate sputum throat swab culture within 2 month prior consent Patient must able provide write informed consent/assent prior study related procedure ; parent/guardian must able give write informed consent necessary prior study related procedure At high risk disease progression define one follow patient population : FEV1 ≤ 50 % predicted time consent OR Completed participation CPAI006 ( Visit 20 ) . Patients withdraw CPAI006 prior complete course AZLI study visit eligible protocol . Patients serious active medical psychiatric illness , opinion investigator , would interfere patient treatment , assessment compliance protocol dosing requirement Patients hypersensitivity component drug product Currently enrol another clinical trial Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>CF</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>EAP</keyword>
	<keyword>Expanded access</keyword>
	<keyword>AZLI</keyword>
	<keyword>Aztreonam lysine</keyword>
</DOC>